Connect with us

News

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Loop Industries, Turquoise Hill Resources, Reata Pharmaceuticals, and Evolus and Encourages Investors to Contact the Firm

gbafNews28

NEW YORK, Oct. 28, 2020 — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Loop Industries, Inc. (NASDAQ: LOOP), Turquoise Hill Resources Ltd. (NYSE: TRQ), Reata Pharmaceuticals, Inc. (NASDAQ: RETA), and Evolus, Inc. (NASDAQ: EOLS). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Loop Industries, Inc. (NASDAQ: LOOP)

Class Period: September 24, 2018 to October 12, 2020

Lead Plaintiff Deadline: December 14, 2020

On October 13, 2020, Hindenburg Research published a report alleging, among other things, that “Loop’s scientists, under pressure from CEO Daniel Solomita, were tacitly encouraged to lie about the results of the company’s process internally.” The report also stated that “Loop’s previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were ‘technically and industrially impossible,’” according to a former employee. Moreover, the report alleged that “Executives from a division of key partner Thyssenkrupp, who Loop entered into a ‘global alliance agreement’ with in December 2018, told us their partnership is on ‘indefinite’ hold and that Loop ‘underestimated’ both costs and complexities of its process.”

On this news, the Company’s share price fell $3.78, or over 32%, to close at $7.83 per share on October 13, 2020.

The complaint, filed on October 13, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that Loop scientists were encouraged to misrepresent the results of Loop’s purportedly proprietary process; (2) that Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) that, as a result, the Company was unlikely to realize the purported benefits of Loop’s announced partnerships with Indorama and Thyssenkrupp; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the Loop class action go to: https://bespc.com/cases/Loop

Turquoise Hill Resources Ltd. (NYSE: TRQ)

Class Period: July 17, 2018 to July 31, 2019

Lead Plaintiff Deadline: December 14, 2020

Turquoise Hill is an international mining company focused on the operation and development of the Oyu Tolgoi copper-gold mine in Southern Mongolia (“Oyu Tolgoi”), which is the Company’s principal and only material resource property. Turquoise Hill’s subsidiary, Oyu Tolgoi LLC, holds a 66% interest in Oyu Tolgoi, and the remainder is held by the Government of Mongolia.

Rio Tinto plc and Rio Tinto Limited are operated and managed together as single economic unit and engage in mining and metals operations in approximately 35 countries. Through their subsidiaries, Rio Tinto owns 50.8% of Turquoise Hill. A Rio Tinto subsidiary, Rio Tinto International Holdings, Inc. (“Rio Tinto International” or “RTIH”; and collectively with Rio Tinto plc and Rio Tinto Limited, “Rio Tinto”), is also the manager of the Oyu Tolgoi project, including having responsibility for its development and construction.

On July 31, 2019, Turquoise Hill issued a press release and Management Discussion & Analysis (“MD&A”) making further disclosures about the status of the project, including that Turquoise Hill took a $600 million impairment charge and a substantial “deferred income tax recognition adjustment” tied to the Oyu Tolgoi project, and that it suffered a loss in the second quarter. The next day, before the market open, Rio Tinto issued a release concerning in part the project status, including that it had also taken an impairment charge related to the Oyu Tolgoi project, of $800 million.

Following this news, on August 1, 2019, Turquoise Hill’s common stock price closed at $0.53 per share, down 8.62% from the prior day’s closing price of $0.58 per share.

The complaint, filed on October 15, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements and omitted to disclose material facts regarding the Company’s business and operations. Specifically, defendants made false and or misleading statements and/or failed to disclose that: (i) the progress of underground development of Oyu Tolgoi was not proceeding as planned; (ii) there were significant undisclosed underground stability issues that called into question the design of the mine, the projected cost and timing of production; (iii) the Company’s publicly disclosed estimates of the cost, date of completion and dates for production from the underground mine were not achievable; (iv) the development capital required for the underground development of Oyu Tolgoi would cost substantially more than a billion dollars over what the Company had represented; and (v) Turquoise Hill would require additional financing and/or equity to complete the project.

For more information on the Turquoise Hill class action go to: https://bespc.com/cases/TRQ

Reata Pharmaceuticals, Inc. (NASDAQ: RETA)

Class Period: October 15, 2019 to August 7, 2020

Lead Plaintiff Deadline: December 14, 2020

Reata is a clinical stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.

Among Reata’s drug candidates under development is omaveloxolone, which is in Phase 2 clinical development to treat Friedreich’s ataxia (“FA”).  Following the announcement of positive data from the MOXIe Part 2 study of omaveloxolone for FA in October 2019, the Company represented that it would seek submission for marketing approval of omaveloxolone for the treatment of FA in the U.S. with the U.S. Food and Drug Administration (“FDA”).

On August 10, 2020, Reata issued a press release announcing its second quarter 2020 financial results, wherein it disclosed that the FDA is “not convinced that the MOXIe Part 2 results” of the Company’s study assessing omaveloxolone for the treatment of FA “will support a single study approval without additional evidence that lends persuasiveness to the results,” and that, “[i]n preliminary comments for [a] meeting, the FDA stated that [Defendants] will need to conduct a second pivotal trial that confirms the mFARS [modified Friedreich’s Ataxia Rating Scale] results of the MOXIe Part 2 study with a similar magnitude of effect.”

On this news, Reata’s stock price fell $51.79 per share, or 33.16%, to close at $104.41 per share on August 10, 2020.

The Complaint, filed on October 15, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that:  (i) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

For more information on the Reata class action go to: https://bespc.com/cases/REATA

Evolus, Inc. (NASDAQ: EOLS)

Class Period: February 1, 2019 to July 6, 2020

Lead Plaintiff Deadline: December 15, 2020

Beginning in February 2019, Evolus embarked on a public campaign to hype the market right before the commercial launch of its sole leading product Jeuveau™. To secure an aggressive growth and an rapid influx of revenue, Evolus disseminated dozens of public statements in which they promoted Jeuveau™ as a proprietary formulation of the botulinum toxic type A complex, purportedly developed by Korean bioengineering company Daewoong through years of clinical research and millions of dollars’ worth of investment in research and development. Among other things, Evolus promised investors that it would attain the number two U.S. market position within 24 months of launch.

The investing public learned the real truth about Jeuveau™ on July 6, 2020 when the U.S. International Trade Commission (“ITC”) issued its Initial Final Determination in a case brought by Allergan and Medytox against Evolus, alleging that Evolus stole certain trade secrets to develop Jeuveau™. Coming as a great surprise to the unsuspecting investors, the ITC Judge found that Evolus misappropriated the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture. To make things even more catastrophic, the ITC Judge recommended a ten-year long ban on Evolus’ ability to import Jeuveau™ into the United States and a ten-year long cease and desist order preventing Evolus from selling Jeuveau™ in the United States.

On this news Evolus’s share price declined sharply, falling 37% over the course of two trading days, to close at $3.35 on July 8, 2020. Following the news of the ITC’s Initial Final Determination and the subsequent price drop of Evolus’s common shares, several securities analysts downgraded Evolus’s rating and significantly lowered the Company’s price target.

The complaint, filed on October 16, 2020, alleges that throughout the Class period defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company’s business, operational, and compliance policies. Specifically, defendants made false and/or misleading statements and failed to disclose to investors that: (i) the real source of botulinum toxin bacterial strain as well as the manufacturing processes used to develop Jeuveau™ originated with and were misappropriated from Medytox; (ii) sufficient evidentiary support existed for the allegations that Evolus misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau™; (iii) as a result, Evolus faced a real threat of regulatory and/or court action, prohibiting the import, marketing, and sale of Jeuveau™; which in turn (iv) seriously threatened Evolus’ ability to commercialize Jeuveau™ in the United States and generate revenue; and (v) any revenues generated from the sale of Jeuveau™ were based on Evolus’ unlawful activities, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox.

For more information on the Evolus class action go to: https://bespc.com/cases/EOLS

About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. Marion Passmore, Esq. (212) 355-4648 [email protected] www.bespc.com

Primary Logo

News

DataTribe Announces Third Annual Cybersecurity Start-Up Challenge Finalists

gbafNews28

DataTribe, a global cyber foundry that invests in and co-builds next-generation cybersecurity and data science companies, announced today the finalists of its third annual DataTribe Challenge. The competition is poised to identify seed stage start-ups with a vision to disrupt cybersecurity and data science.

This years DataTribe Challenge submissions truly exemplified how the world has changed and where new-category defining technologies are coming from. We received submissions from all around the world and our finalists represent technologies that are 3-4 generations ahead of the existing commercial products, said Mike Janke, Co-founder of DataTribe. We are thrilled to welcome these finalists to compete as the winner of this years competition.

In a virtual event format this year, finalists will present a pitch and answer questions from judges on December 10, 2020. Three finalists will split $20,000 in prize money, and one winner will be eligible to receive up to $2 million in seed capital from DataTribe.

Finalists:

  • oak9: Based in Chicago, IL, oak9 enables developers to accelerate delivery while providing comprehensive security. The oak9 platform analyzes infrastructure-as-code and builds security into cloud native applications so they are secure and compliant by-design.
  • Scanta: Based in San Francisco, CA, Scantas mission is to secure conversational systems from adversarial attacks. Through the combination of AI and cybersecurity, Scanta’s security platform identifies and prevents attacks on a wide range of conversational systems.
  • SightGain: Based in Washington, DC, SightGain is the only cybersecurity risk management platform that evaluates security readiness by testing how well both production systems and personnel detect and prevent actual malicious attacks.

In addition to presentations from finalists during the Finalists Event this year, the CyberWires Chief Analyst, Rick Howard, will host experts from The CyberWire’s Hash Table for an insightful discussion of key cyber trends in 2021.

About DataTribe

DataTribe is a startup foundry that invests in and co-builds world class startups focused on generational leaps in cybersecurity and data science. Founded by leading investors, start-up veterans and alumni of the U.S. intelligence community, DataTribe commits capital, in-kind services, access to an unparalleled network, and decades of professional expertise to give their companies an unfair advantage. DataTribe is headquartered in the Washington-Baltimore metro area, in Fulton, Maryland. For more information, visit https://datatribe.com.

Danielle Ostrovsky

Hi-Touch PR

410-302-9459

[email protected]

Continue Reading

News

H.I.G. Growth Partners Completes Strategic Transaction with The Center for Digestive Health and Pinnacle GI Partners

gbafNews28

H.I.G. Growth Partners (“H.I.G.”), the dedicated growth capital investment affiliate of H.I.G. Capital, is pleased to announce that one of its affiliates has completed a strategic investment in Pinnacle GI Partners (Pinnacle GI or the Company), the affiliated management services organization for The Center for Digestive Health (CDH). CDH is a premier provider of digestive health services in the state of Michigan.

Partha Nandi MD, FACP from CDH will serve as President and Practice CEO for Pinnacle GI. Dr. Nandi stated, Our goal in partnering with H.I.G. is to create excellence in gastrointestinal care throughout Michigan. We have a shared vision to leverage the best practices of The Center for Digestive Health throughout the region to deliver innovative clinical solutions to patients, participating payers and major employers. Dr Nandi added, Pinnacle GI is passionate about preserving independent gastroenterology practices for physicians in Michigan and the region.

Mark Tricolli, Managing Director with H.I.G., said, We identified the gastroenterology practice management sector as an area for investment given the strong industry tailwinds driven by an aging population and a higher awareness of GI-related illnesses. We are very excited to partner with the doctors, employees, shareholders and management team of CDH, which has significant infrastructure in place to support continued growth in Michigan, an underserved and significantly fragmented market.

Scott Fraser, the former President of Practice Management at Physicians Endoscopy and a former founding executive of EndoChoice, Inc., will join the Companys Board of Directors. Mr. Fraser brings over 20 years of experience in the gastroenterology space, including developing and executing against growth plans and rapidly scaling multiple GI companies.

KPMG served as the exclusive financial adviser to The Center for Digestive Health, with Foley & Lardner LLP serving as legal advisor. McDermott, Will & Emery served as legal advisor to H.I.G. Debt financing to support the recapitalization was provided by Deerpath Capital Management, L.P.

About The Center for Digestive Health

The Center for Digestive Health is a leading gastroenterology practice based in Michigan with 10 locations and 19 providers, ranking it amongst the most sizable gastroenterology physician groups in the United States. The Company provides comprehensive gastroenterology physician services and a fully integrated suite of ancillary services including anesthesia, pathology, infusion and clinical research. For more information, please visit www.troygastro.com.

About H.I.G. Growth Partners

H.I.G. Growth Partners is the dedicated growth capital investment affiliate of H.I.G. Capital, a leading global private equity investment firm with $42 billion of equity capital under management.* H.I.G. Growth seeks to make both majority and minority investments in strong, growth-oriented businesses located throughout North America, Europe and Latin America. H.I.G. Growth Partners considers investments across all industries but focuses on certain high-growth sectors where it has extensive in-house expertise such as technology, healthcare, internet and media, consumer products and technology-enabled financial and business services. H.I.G. Growth strives to work closely with its management teams to serve as an experienced resource, providing broad-based strategic, operational, recruiting, and financial management services from a vast in-house team and a substantial network of third-party relationships. For more information, please refer to the H.I.G. website at www.HIGgrowth.com.

* Based on total capital commitments managed by H.I.G. Capital and affiliates.

Mark Tricolli

Managing Director

[email protected]

Continue Reading

News

Pacific Premier Bank Makes $200,000 Grant to Susan G. Komen’s Patient Navigation Initiative for Breast Health in Orange County

gbafNews28

Pacific Premier Bancorp, Inc. (NASDAQ: PPBI), the holding company of Pacific Premier Bank (the Bank), announced today the Bank has contributed a grant of $200,000 to Susan G. Komens recently launched pilot program, the Patient Navigation Initiative (PNI) for Breast Health in Orange County, California. The PNI will provide curriculum-based navigation services to patients in an effort to improve the outcomes among underserved populations who are dying from breast cancer at disproportionately higher rates.

The Bank is the first corporate partner to invest in the program, which addresses health inequalities and improves access to breast cancer care in Orange County, California. Cancer is the second leading cause of death in Orange County. An average of five women per day are diagnosed with breast cancer and one woman dies from the disease every day. Susan G. Komen helps women and men, particularly those with little or no health insurance, receive breast health education, screening, treatment, and support.

Orange County remains a key community for Susan G. Komen to carry out several of the organizations key mission priorities, said Megan Klink, Vice President of Susan G. Komens West Region. Komens Orange County community is poised to do this important, innovative work together with our local partners to tackle cancerthe second leading cause of death in Orange County.

PNI is based on a patient-centered delivery model designed to improve access to healthcare services, guide patients through a complex and confusing healthcare system, and overcome various barriers to healthcare. The pilot initiative will primarily serve low-income, uninsured, or underinsured women.

PNI is the first initiative of its kind in the Susan G. Komen organization to focus on workforce development in order to contribute to earlier detection for Orange County residents battling breast cancer. The program will train and mobilize Community Health Workers and Patient Navigators to assist low-income women in navigating through breast cancer services, treatment, and resources. These trained workers will establish and implement protocols and tracking mechanisms to ensure all patients have access to breast health screenings, mammography, and the support for completing treatment “ key to a cancer patients survival.

Pacific Premiers donation is responsive to the need to address equitable health and well-being for low-income and other vulnerable populations in Orange County, said Steve Gardner, Chairman, President, and CEO of Pacific Premier Bancorp, Inc. We are proud to be a key health equity partner with Susan G. Komen to address this gap in care and build a strategic initiative that will benefit not only underserved patients, but also our local economy. We see this as an enormous avenue to strengthen the role that Patient Navigators play in healthcare delivery and care coordination, aiming at improving a breast cancer patients access to care.

This unique 3-year PNI pilot program will begin with residents of Orange County, with a long-term goal for Susan G. Komen to replicate the program and impact in other communities around the country.

For more information about the Patient Navigation Initiative from Susan G. Komen, visit komenoc.org.

About Susan G. Komen

Susan G. Komen is the worlds largest breast cancer organization, funding more breast cancer research than any other nonprofit while providing real-time help to those facing the disease. Komen has set a Bold Goal to reduce the current number of breast cancer deaths by 50 percent in the U.S. by 2026. Komen was founded in 1982 by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzys life. Komen is working to better the lives of those that face breast cancer in Orange County. Through events like the MORE THAN PINK WALK in Orange County, Komen has invested more than $42 million in community breast health programs and has helped contribute to the more than $920 million invested globally in research. For more information, visit komenoc.org.

About Pacific Premier Bancorp, Inc.

Pacific Premier Bancorp, Inc. (Nasdaq: PPBI) is the parent company of Pacific Premier Bank, a California-based commercial bank focused on serving small, middle-market, and corporate businesses throughout the western United States in major metropolitan markets in California, Washington, Oregon, Arizona, and Nevada. Founded in 1983, Pacific Premier Bank has grown to become one of the largest banks in the western region of the United States, with approximately $20 billion in total assets. Pacific Premier Bank provides banking products and services, including deposit accounts, digital banking, and treasury management services, to businesses, professionals, entrepreneurs, real estate investors, and nonprofit organizations. Pacific Premier Bank also offers a wide array of loan products, such as commercial business loans, lines of credit, SBA loans, commercial real estate loans, agribusiness loans, franchise lending, home equity lines of credit, and construction loans. Pacific Premier Bank offers commercial escrow services and facilitates 1031 Exchange transactions through its Commerce Escrow division. Pacific Premier Bank offers clients IRA custodial services through its Pacific Premier Trust division, which has approximately $15 billion of assets under custody and approximately 44,000 client accounts comprised of self-directed investors, financial institutions, capital syndicators, and financial advisors. Additionally, Pacific Premier Bank provides nationwide customized banking solutions to Home Owners’ Associations and Property Management companies. Pacific Premier Bank is an Equal Housing Lender and Member FDIC. For additional information about Pacific Premier Bancorp, Inc. and Pacific Premier Bank, visit our website: www.ppbi.com.

Pacific Premier Bancorp, Inc.

Steven R. Gardner

Chairman, President and Chief Executive Officer

949-864-8000

Brett Villaume

SVP, Director of Investor Relations

949-553-9042

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News14 mins ago

Centripetal Ranked Number 124 of the Fastest Growing Companies in North America on Deloitte’s 2020 Technology Fast 500™

Centripetal today announced it ranked 124th on Deloittes Technology Fast 500„¢, a ranking of the 500 fastest growing technology, media,...

gbafNews28 gbafNews28
News14 mins ago

Viseon MaxView™ System Accelerates Adoption of Minimally Invasive Spine Surgery Procedures

Viseon, Inc., a leader in minimally invasive spine surgery visualization technologies, today announced MaxView„¢ facilitates more rapid adoption of Minimally...

gbafNews28 gbafNews28
News14 mins ago

BlackRock Unveils New Offering to Power Investors’ Transition to Net Zero Emissions

Building on BlackRocks strength in risk management through the Aladdin platform, BlackRock today announced it has created Aladdin Climate to...

gbafNews28 gbafNews28
News14 mins ago

Kount Partners With Snowflake to Deliver Actionable Customer Insights for eCommerce Providers to Improve Customer Experience, Lower Friction, Increase Conversions and Uncover Cross-sell and Upsell Opportunities

Kount, the leader in identity trust and digital fraud protection, today announced a partnership with Snowflake, provider of Data Cloud,...

gbafNews28 gbafNews28
News14 mins ago

Biodesix Publishes Extended Analyses of the Nodify XL2® Lung Nodule Test

Biodesix, Inc. (Nasdaq: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced publication of...

gbafNews28 gbafNews28
News14 mins ago

HSBC USA Observes #GivingTuesday with $400,000 In New Contributions to Feeding America, American Red Cross and to Address Evictions Crisis

HSBC Bank USA kicks off the year-end giving season with announcements on Giving Tuesday of increased contributions to organizations providing...

gbafNews28 gbafNews28
News14 mins ago

NanoString Unveils Spatial Molecular Imaging Platform, Complementing GeoMx DSP to Provide Compelling Product Roadmap for Spatial Biology

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the development...

gbafNews28 gbafNews28
News14 mins ago

Pacific Premier Bank Makes $200,000 Grant to Susan G. Komen’s Patient Navigation Initiative for Breast Health in Orange County

Pacific Premier Bancorp, Inc. (NASDAQ: PPBI), the holding company of Pacific Premier Bank (the Bank), announced today the Bank has...

gbafNews28 gbafNews28
News14 mins ago

H.I.G. Growth Partners Completes Strategic Transaction with The Center for Digestive Health and Pinnacle GI Partners

H.I.G. Growth Partners (“H.I.G.”), the dedicated growth capital investment affiliate of H.I.G. Capital, is pleased to announce that one of...

gbafNews28 gbafNews28
News14 mins ago

DataTribe Announces Third Annual Cybersecurity Start-Up Challenge Finalists

DataTribe, a global cyber foundry that invests in and co-builds next-generation cybersecurity and data science companies, announced today the finalists...